Tag Archives: PrEP

Study of injectable PrEP reports the best efficacy seen yet for any form of PrEP in women

HPTN 084 study finds significantly lower adherence in women taking daily PrEP pills A second study of an injectable HIV drug used to prevent HIV has had its randomised phase stopped early after it became clear that giving women a two-monthly injection of a prevention drug resulted in nearly nine times fewer infections than giving… Read More »

How to Use Meal Prep and Batch Cooking to be Consistent with Healthy Eating

Meal planning and prepping is one of the best tools you can gain for ensuring you are getting nutrient-dense meals throughout your week. Planning ahead removes decision fatigue, saves you time, and prevents you from making decisions you don’t truly want during a moment of “hanger.” There’s no better feeling than starting off your Monday… Read More »

Truvada, not Descovy, should be the first choice for PrEP, US experts say

Although there are now two drug combinations which can be used for HIV prevention as PrEP, there is stronger and broader evidence for the older combination (Truvada), which should remain the first-line choice, four leading US doctors argue in the Annals of Internal Medicine today. The authors emphasise the excellent safety profile of both drugs.… Read More »

Marked changes in gay men’s relationship agreements and condom use in the PrEP era

A recent Australian study found that gay couples’ agreements regarding casual sex outside their relationships have changed markedly in the era of pre-exposure prophylaxis (PrEP). Nearly 40% of PrEP users in relationships had agreements that allowed for condomless sex with casual partners. Additionally, 34% of PrEP users engaged in condomless casual sex despite being in… Read More »

Hepatitis C incidence is low among Canadian men on PrEP

New cases of hepatitis C virus (HCV) infection among Canadian gay and bisexual men taking pre-exposure prophylaxis (PrEP) were uncommon compared with rates previously reported in Europe, according to research presented this week at the AASLD Liver Meeting in Boston. “This low incidence is reassuring since studies have shown that risk behaviour associated with sexually… Read More »

FDA Approves Descovy (emtricitabine and tenofovir alafenamide) for HIV Pre-Exposure Prophylaxis (PrEP)

Print this page FOSTER CITY, Calif.–(BUSINESS WIRE)–Oct. 3, 2019– Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved a pre-exposure prophylaxis (PrEP) indication for Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets; F/TAF). Descovy for PrEP™ is indicated to reduce the risk of sexually acquired HIV-1 infection in adults and… Read More »